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Abstract: Silk is a natural polymer with unique physicochemical and mechanical properties which
makes it a desirable biomaterial for biomedical and pharmaceutical applications. Silk fibroin (SF) has
been widely used for preparation of drug delivery systems due to its biocompatibility, controllable
degradability and tunable drug release properties. SF-based drug delivery systems can encapsulate
and stabilize various small molecule drugs as well as large biological drugs such as proteins and
DNA to enhance their shelf lives and control the release to enhance their circulation time in the
blood and thus the duration of action. Understanding the properties of SF and the potential ways
of manipulating its structure to modify its physicochemical and mechanical properties allows for
preparation of modulated drug delivery systems with desirable efficacies. This review will discuss
the properties of SF material and summarize the recent advances of SF-based drug and gene delivery
systems. Furthermore, conjugation of the SF to other biomolecules or polymers for tissue-specific
drug delivery will also be discussed.
Keywords: silk fibroin; drug delivery; gene delivery; controlled release; bioconjugation
1. Introduction
Polymeric drug delivery systems have emerged as a new efficient alternative to the conventional
formulations to provide a reservoir to the active pharmaceutical ingredients (APIs), improve their
physicochemical properties, and overcome some of the major challenges in drug delivery including
specific targeting, intracellular transport, and biocompatibility in order to improve the treatment
efficiency and life quality of patients [1–4]. An ideal drug delivery system should stabilize the loaded
API, allow for modulating its release kinetics and minimize its adverse effects by tissue-specific
targeting, especially in the case of highly toxic drugs such as anticancer agents. Silk has been
known as a valuable natural material for the fabric industry for centuries, but in the past decades
it has attracted immense attention as a promising biopolymer for biomedical and pharmaceutical
applications [5–7]. Silk protein possesses a unique combination of properties which is rare among
natural polymers. It also enjoys desirable characteristics such as mild aqueous possessing conditions,
high biocompatibility and biodegradability, and the ability to enhance the stability of the loaded APIs
(e.g., proteins, pDNA, and small molecule drugs) [4,5,8,9]. Moreover, silk fibroin (SF) solution can be
processed by various methods to produce different types of delivery systems including hydrogels,
films, scaffolds, microspheres, and nanoparticles [10]. SF exists in three different structural forms: Silk
I, Silk II and Silk III. Silk I exists in water-soluble form and consists of a high percentage of α-helix
domains in addition to random coils [11]. Contrarily, Silk II has mainly β-sheet structure and is more
stable and water-insoluble, while Silk III prevails at the water/air interface [12]. The transformation
from Silk I to Silk II can be tuned by different methods including organic solvent treatment, physical
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shear, electromagnetic fields, or chemical processing [13,14]. These properties can be utilized in the
pharmaceutical industry for producing micro- and nano particles and nano-fibrils or for coating other
pharmaceutical preparations such as liposomes [15,16]. Moreover, the availability of carboxyl and
amino groups in the SF allows for bio-functionalization with various biomolecules or ligands which
could be used for targeted drug delivery [17]. The two main strategies for functionalizing silk protein
are chemical conjugation and genetic modification of silk by chainging the amino acid composition or
adding a fragment to obtain a specific function [18]. A large proportion of drug formulations including
the vast majority of anticancer drug formulations are prepared for parenteral administration, resulting
in direct contact with the blood components. Thus, the drug carriers used in such formulations
should not induce any haematological toxicity or immune responses [3], which necessitates the use of
biocompatible polymers in the formulation. Furthermore, designing delivery systems for biological
drugs such as vaccines and antibodies requires maintaining their physical stability as well as their
biological activity, which is more crucial for the controlled release systems [19]. This is mainly due to
the higher sensitivity of the biological compounds, especially the protein-based therapeutics, to many
of the processing conditions throughout the delivery system preparation compared to small molecule
drugs, which limits the processing strategies [20,21]. Hence, loading the biological therapeutics into
a compatible polymer can increase their stability and consequently their half-life [22]. Moreover,
incorporating the APIs into a natural biocompatible protein such as SF has multiple advantages e.g.,
preserving the API [23], improving the mechanical properties of the formulation [6], modifying drug
release kinetics [24–27], enhancing cell adhesion [16], and compatibility with blood components [25].
The versatility of SF protein processing and formulatingmethods allows the preparation of awide range
of drug carriers with different sizes and morphologies using unmodified or engineered SF (Figure 1).
Unmodified SF carriers have been used to deliver various anticancer drugs such as doxorubicin [28],
paclitaxel [29], curcumin [9,30], and cisplatin [31]. In this review, the main strategies for obtaining
different SF-based drug delivery systems and the recent methods for generating functionalized SF for
controlled or targeted drug and gene delivery will be discussed.
Figure 1. A diverse set of physical assemblies and chemical methods for preparing a variety of silk
fibroin (SF) formats for pharmaceutical and biomedical applications.
2. Physiochemical Properties of Silk Fibroin
SF possesses a unique combination of mechanical and biological properties and exhibits special
features of both synthetic and natural polymers [32,33]. Typically, silk represents softness in the clothing
industry, but it is considered one of the most robust natural biomaterials due to its tensile strength and
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modulus [34]. This feature is important for the polymers involved in bone tissue regeneration
as mechanical performance of the polymer is of utmost importance for such applications [35].
SF demonstrates excellent stability under high thermal stress (higher than 250 ◦C) [36].
2.1. Biocompatibility
SF is a biocompatible material that has been officially recognized by the Food and
Drug Administration (FDA) for the development of a plethora of nanotechnological tools [37].
The biocompatibility of silk has been studied extensively over the past two decades. The majority of
the studies have reported excellent biocompatibility and relatively lower immunogenic response in
comparison to other common degradable biological polymers in the pharmaceutical industry such
as polylactide (PLA), poly(lactic-co-glycolic acid) (PLGA) and collagen [22,38,39]. Cytocompatibility
studies on SF formats revealed high compatibility with different cell lines including hepatocytes,
osteoblasts, fibroblasts, endothelial cells and mesenchymal stem cells (MSCs) [40,41]. During SF
processing, organic solvents such as methanol and hexafluoroisopropanol (HFIP) are used to crosslink
SF via inducing structural transformation (α helix to β sheet), which has been found responsible for
the inflammatory potential of SF formulations [42]. However, mild processing conditions that avoid
the use of organic solvents have been used to avoid these inflammatory responses [43]. An evaluation
of the levels of lymphocyte activating factor IL-1β and inflammatory cyclooxygenase-2 (COX-2) gene
expression in relation to SF stimulation did not show any significant differences from those of collagen
or PLA, indicating very low immunogenicity [44]. Another study has evaluated the biocompatibility of
scaffolds consisting of a combination of calciumpolyphosphate (CPP) and SF used for the reconstruction
of cartilage and bone defects [45]. The results showed a tangible increase in tissue biocompatibility
and osteogenicity of SF-CPP scaffolds in comparison to CPP scaffolds [45].
2.2. Mechanical Properties
Mechanical stiffness is a key property of SF-based formulations for pharmaceutical and biomedical
applications. The SF material used in tissue engineering, for example, must match the stiffness of
the targeted tissue. The stiffness can also affect the stability and degradability of the SF polymer [46].
Many polymers that have been used in drug delivery devices, such as PLGA and collagen, lack sufficient
mechanical strength. A common strategy to enhance the mechanical strength of the biopolymers
such as collagen is crosslinking. However, the crosslinking reaction could result in undesirable
consequences such as cellular toxicity and immunogenicity [47]. SF possesses robust β-sheet structure
which provides excellent mechanical properties without the need for any harsh crosslinking procedures.
Based on the β-sheet content, SF can transform into different formats including liquid, hydrogels,
or scaffolds [5]. Measurements of mechanical strength are usually obtained from Young’s modulus
using nanoindentation techniques [48]. SF exhibits high tensile strength and resistance to compressive
force making it a very suitable material for drug delivery and tissue engineering [49]. Moreover,
the removal of sericin during the degumming process results in a 50% increase in tensile strength [50]
which makes SF more stable during physical pharmaceutical processing.
2.3. Stability
The stability of the polymeric materials is one of the most important factors in the production of
pharmaceutical formulations. Although biopolymers are preferred to their synthetic counterparts for
clinical applications due to their biocompatibility and biodegradability, they must also meet certain
stability standards to be considered for utilisation in the pharmaceutical industry. One of the common
stability problems of pure SF solution is aggregation or gelation during long-term storage. SF is
available in soluble form (with high content of α- helix and random coil) and insoluble form (with
high content of β-sheet). Depending on the pharmaceutical preparation, either form should be used
and maintained. Storing the soluble SF in highly humid conditions results in a transformation from
α-helix and random coil to β-sheet which could lead to gelation and a decrease in the stability of the SF
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solution [51,52]. SF shows excellent stability under thermal stress compared to other proteins. The best
indicator for protein thermal stability is the glass transition temperature (Tg) which in the case of SF is
affected by its β-sheet content. The Tg of SF films is approximately 175 ◦C and the protein remains
stable up to 250 ◦C which is desirable for formulation processing. On the other hand, Tg of the frozen
SF solution can go to −34 ◦C [53] which is also advantageous in low temperature pharmaceutical
processing. Furthermore, the degree of crystallinity and porosity of SF films are also affected by
Tg [54] The increase in β-sheet content of SF causes a transformation from Silk I to Silk II, refelected by
a significant change in Tg which changes the degree of crystallinity. Stability of the SF in physiological
fluids is another important issue for its biomedical applications. SF could be protected from enzymatic
degradation within the body by coating with polymers such as polyethylene glycol (PEG) in order to
improve the delivery of the associated drugs to the site of action.
2.4. Degradability
Degradability is an important property of biological materials. Although biodegradability is
amain advantage of SF in clinical applications, this propertymakes pure SF particles liable to proteolytic
enzymes. The degradation rate of SF can be regulated by modifying the molecular weight, the degree
of crystallinity, morphological features, or crosslinking [56]. However, the degree of crystallinity and
crosslinking are not the only approaches to stabilize SF against degradation. For example, an in vitro
enzymatic degradation experiment revealed that SF sheets slightly transformed from Silk II to Silk
I crystalline structure when exposed to collagenase IA. However, when protease XIV was used,
the majority of the SF sheets transformed to Silk I leading to a higher degree of crystallinity. Although
the degradation time was 15 days in both cases, the degradation rate was significantly lower for
protease XIV compared to collagenase IA [57]. Another study reported a predictable loss of mechanical
integrity due to SF degradation [58]. Incubation with protease led to an exponential decrease in the
SF filament diameter to 66% of the initial diameter after 10 weeks. Gel electrophoresis indicated
a decreasing amount of the silk 25 kDa light chain and a shift in the molecular weight of the heavy
chain with increasing incubation time with protease XIV [58]. The enzymatic degradation behavior of
SF was studied by Wongpinyochit et al. [55] using three different proteases (papain, chymotrypsin,
and protease XIV) over a period of 20 days. As shown in Figure 2, the cleavage sites vary from one
protease to another, leading to variations in degradation rate. The degradation rate was higher in the
presence of chymotrypsin compared to papain and protease XIV but the latter two did not have any
significant difference. The degradation rate does not only rely on cleavage sites but also on the enzyme
accessibility, SF format, and the secondary structure of the SF [55]. A previous in vivo degradation
study in rats found that SF degredation is also related to the phagocytic activity of the cells (fibroblasts)
and the presence of sericin with SF [59]. The raw silk (SF and Sericin) has a higher degradation rate
than pure SF because sericin promotes degredation by the cells [59].
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Figure 2. Two-dimensional schematic illustration of silk structure including the heavy chain (i.e.,
N-terminus, crystalline β-sheets, amorphous, and C-terminus) and light chain (A). Enzymatic
specificities of proteolytic enzymes for the silk sequences (B). Number of cleavage sites of proteolytic
enzymes on different silk domains (C). Reprinted from [55] with permission from American Chemical
Society [2018].
3. SF-Based Drug Delivery Systems
Delivery of APIs in sustained and controlled release forms is important for many clinical
applications. Selection of the particle size, composition, and other features depends on the type of the
delivery system and the route of administration. Moreover, using biocompatible and mechanically
durable polymers with mild fabrication and processing conditions in such delivery systems is
advantageous for preserving the bioactivity of the loaded APIs. As discussed earlier, SF meets all
these requirements which makes it a promising candidate for drug delivery [5,60]. SF-based drug
delivery systems can be fabricated by different methods, each resulting in a delivery system with
unique properties such as modified release kinetics, stability, and other features which could be of
benefit in various applications. Various types of SF-based drug delivery systems have been designed
including hydrogels, films, micro- and nanoparticles, nanofibers, lyophilized sponges as well as
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SF-coated polymeric particles. In the following section, some of the most widely studied SF-based
drug delivery systems are reviewed.
3.1. Hydrogels
SF aqueous solution was used to generate hydrogels by different methods. The transition from
solution to gel can be triggered by physiochemical or chemical processes using natural polymers or
synthetic reagents [61]. The physicochemical processes include shearing (spinning), water exclusion
via evaporation or osmotic stress, electric field, and heating [62]. The gel form is stabilized because of
thermodynamically stable β-sheets which result in a stable gel form in physiological conditions unless
extensively degraded by enzymes or oxidative reactions [62]. One recent study used curcumin-loaded
gel scaffolds prepared by electrogelation for wound healing [63]. The prepared gel formulation not only
improved protein adsorption and sustained the release of curcumin, but also enhanced bacterial growth
inhibition by 6-fold against S. aureus [63]. Since protein adsorption on substrates is a key factor for cell
growth and proliferation, SF gel scaffolds can serve in wound healing by promoting cell proliferation.
Sundarakrishnan et al. [64], adapted a chemical approach using horseradish peroxidase (HRP) and
hydrogen peroxide to prepare SF hydrogels that were subsequently crosslinked with di-tyrosinase,
and loadedwith phenol red in order to develop a self-reporting pH system for in vitro environment [64].
Addition of phenol red during di-tyrosine crosslinking resulted in stable entrapment of phenol red
within SF hydrogel network due to covalent interactions between phenol red and tyrosine and also
prevented leaking [64].
3.2. Silk Films
Film preparation from SF has attracted more attention recently due to its huge potential as
a biomaterial in pharmaceutical formulations and tissue engineering [65]. SF films can be simply
prepared by casting an aqueous SF solution [66]. However, there are other reported SF film preparation
techniques such as vertical deposition [67], spin coating [68], centrifugal casting [65], and spin assisted
layer-by-layer assembly [69]. Terada et al. [68] investigated the behavior of spin-coated SF films treated
with different ethanol concentrations. Alcohol concentrations of 80% or less resulted in a jelly-like
hydrogel layer while treatment with more than 90% alcohol provided a rigid film surface. This change
in morphology affected the attachment of the fibroblast cells to the SF films. Fibroblasts aggregated on
the rigid surface rather than attaching individually to the hydrogel surface [68]. Another study found
that blending SF with other polymers such as sodium alginate (SA) before casting the film results in
a miscible and transparent film and also induces a structural change in SF [70]. Manipulating the SF/SA
blending ratio shifted the SF conformation to the higher β-sheet content. Moreover, mixing SA with SF
enhancedwater permeability, swelling capacity and tensile strength of SF films [70]. Hence, SF/SA blend
can provide unique tunable chataristics that can be benificial in pharmaceutical applications.
3.3. Silk Particles
As discussed earlier, the are an increasing number of SF-based systems that have been used
for encapsulating APIs and achieving modulated drug delivery among which nanoparticle delivery
systems have been studied themost, especially for anticancer drugs. One example of such systems is the
lysosomotropic SF nanoparticles designed by Seib et al. [28] for pH-dependent release of the anticancer
drug doxorubicin in order to overcome drug resistance. SF nanoparticles are largely employed for
controlled release of the loaded drug at the site of action. SF nanoparticles can be fabricated by various
methods, for example polyvinyl alcohol (PVA) blends, which are used for fabricating SF spheres
with controllable sizes and shapes [71] (Table 1). The determinant factors for drug distribution and
encapsulation efficiency in such systems are their charge and lipophilicity. Modifying these factors
results in different drug release profiles [72]. Furthermore, addition of PVA results in a tangible
improvement in the morphology of the SF-particles [73]. One of the popular methods for fabrication
SF particles is the salting-out method. For example, Lammel et al. [74] produced SF particles with
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controllable sizes ranging from 500 nm to 2 µm using potassium phosphate as the salting out agent.
The β-sheet structure and zeta potential of the SF particles were affected by the pH of the potassium
phosphate solution [66,74]. In another study conducted by Tian et al. [75] SF nanoparticles were
prepared using the salting out method, loaded with a combination of doxorubicin and Fe3O4 magnetic
nanoparticles and driven to the target tissue using an external magnetic field to achieve tissue-specific
targeted delivery [75]. It was also found that the entrapment efficiency of doxorubicin can be tuned by
changing the concentration of Fe3O4 in the formulation [75]. However, the size of SF particles produced
by potassium phosphate was over 500 nm, which is not ideal for drug delivery. Recently, Song et al. [43]
producedmagnetic SF nanoparticles (MSNPs) with size range of 90–350 nm by using sodium phosphate.
The size and morphology of the MSNPs were governed by the SF concentration, the ionic strength and
pH of the salting-out agent (Figure 3) [43]. Compared to potassium phosphate, sodium phosphate
produced smaller particles and the size did not increase significantly with increasing SF concentration
and ionic strength, providing a promising method to produce smaller particles with high concentration
for drug delivery. The size of the particles can be further reduced by increasing the pH of the salting-out
agent (Figure 3). Although salting-out and PVA methods are preferred over other methods due to their
simplicity and low toxicity, purifying the SF nanoparticles from excess polymers or salting-out agent
is required. Therefore, Mitropoulos et al. [76] managed to prepare SF particles with spherical shape
using a co-flow capillary device with PVA as the continuous phase and silk solution as the discrete
phase. This device allows for generation of SF spheres (2 µm in size) without the requirement for any
further purification steps. Moreover, the diameter of the spheres can be simply adjusted by changing
the concentration of the polymers, the flow rate, and the molecular weight of the selected polymer [76].
However, the size of the particles produced is not within the desired size range for drug delivery.
A more recent study on the microfluidics has used a microfluidic set up (nano-assembler) to produce
smaller sizes of SF particles (150–300 nm) by a desolvation method [77] (Table 1). It was found that
the characteristics of the SF nanoparticles are controlled by two main factors: Flow rate and flow rate
ratio [77]. The use of microfluidic instrument enabled rapid, reproducible and controlled production of
SF nanoparticles with desirable sizes for drug delivery. However, solvent residues within the particles
and the cost of the equipment should also be taken into account. The properties of the SF particles
can also be manuplated by blending with other polymers. For example, Song et al. [9] have recently
produced SF nanoparticles blended with different amounts of polyethyleneimine (PEI). The size of
the SF nanoparticles was found to increase with increasing SF percentage (Figure 3), while the zeta
potential of the particles decreased with increasing SF amount. This allows to fine tune the drug
delivery through controlling the size and zeta potential of the particles.
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Figure 3. Effects of SF concentration, salt, ionic strength and solution pH to the particle size and
protein secondary structure. (a) Particle diameter as a function of SF concentration when adding SF
solutions (concentration from 0.1–12 mg/mL) to sodium phosphate (Na-P) and potassium phosphate
(K-P) solutions (both at ionic strength 1.25 M, pH 8) at the volume ratio of 1:5. (b) Diameter of SF
particles fabricated with K-P or Na-P as a function of their ionic strength. The SF concentration was
fixed at 5 mg/mL. (c-d) AFM images of particles fabricated by adding SF solution (12 mg/mL) in to
sodium phosphate (c) and potassium phosphate (d). Both solutions are at the ionic strength of 1.25 M
and pH 8. (e) Diameter of SF particles fabricated with Na-P as a function of the Na-P solution pH. (f)
FTIR spectra of particles produced by 1.25 M sodium phosphate at different pH values. It was found
that the use of sodium phosphate, lower ionic strength and higher pH of solution produces smaller SF
particles. Reprinted from Reference [43]; with permission from American Chemical Society [2017].
Table 1. Preparation teqniques of SF micro- and nanoparticles.
Preparation Technique Advantages Disadvantages Particle Size
Self-assembly
Simple and safe procedure
Does not require toxic reagents
Sensitive to temperature and
vigorous mixing
100–200 nm [11]
Salting out
Low cost method
The active ingredient can be loaded
during the particle formation
Salting out agent residue
Relatively high particle size
polydispersity
100–350 nm [43]
500 nm–2 µm [74]
Emulsification
Controllable particle size
Low cost method
Organic solvent or surfactant
residues
170 nm [78]
Desolvation
Simple and quick method
Small particle size
Reproduceable technique
Particle aggregation
Organic solvent residue
35–170 nm [79]
Electrospraying
High purity particles
Very good monodispersity
Requires additional step to
insolubilize SF
59–80 nm [80]
600–1800 nm [72]
Microfluidic methods
Rapid procedure
Mild operation conditions
Controllable particle yield and
particle size
Relatively expensive
Residual salting agent or organic
solvents
150–300 nm [77]
Capillary microdot Simple procedure Organic solvents residue 25–140 nm [81]
Freeze drying Porous particles Large particle size 490–940 µm [17]
Supercritical fluids High drug loading
Expensive technique
Not easy to operate
Requires additional step to
insolubilize SF
50–100 nm [82]
PVA Blending method
Time and energy efficient
No use of organic solvent
PVA residue
5–10 µm [71]
300–400 nm [71]
Nano-imprinting and
inject printing
Tuneable dimensions of different
nanostructures
Complicated method
Not easy to scale up
Not easy to prepare particles
180 nm–50 µm [83]
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4. Applications of Silk Fibroin for Drug and Gene Delivery
Silk has been used as a carrier for delivery of a wide range of therapeutic agents including small
molecule drugs [3], biological drugs [84], and genes [85]. For each class of therapeutic agents, different
formulations have been designed using various silk processing technologies [86]. One of the main
criteria of the SF-based delivery systems is to stabilize the loaded API and manipulate its circulation
time to achieve the required therapeutic effect. In addition, the designed formulations are usually
optimized to obtain a particular application in drug delivery including stabilising the loaded drug,
controlling drug release, and improving cell adhesion [16]. In the following section, an insight into SF
applications in drug and gene delivery will be provided a summary of which is presented in Tables 2
and 3.
4.1. Drug and Gene Stabilization by SF
One of the main goals of incorporating active ingredients such as small molecules or peptides
into SF-based carriers is to stabilise them by different mechanisms including adsorption, covalent
interaction, and/or entrapment [87]. Without a stable interaction between the drug and the SF-based
carrier to maintain the drug activity, sustained drug release cannot be achieved. Aside from a few
exceptions such as growth factors, the majority of the stabilisation approaches rely on entrapping the
drug within the SF-matrix or SF-particles in an equally distributed manner [22]. SF-based biomaterials
are generally stable to changes in temperature [23], humidity [88], and pH [89]. Therefore, they have
been widely studied for enhancing the stability of other materials, for example, encapsulation of
antibiotics such as erythromycin, which has very low stability in water. However, porous SF sponges
managed to sustain its release and maintain its antimicrobial activity against Staphilococcus Aureus for
up to 31 days at 37 ◦C [3]. SF films have also been used for stabilisation of biological compounds.
For example, enhanced stability of horseradish peroxidase (HRP) when loaded on SF films or mixed
with SF solutions has been reported. The enzymatic activity of SF-loaded HRP was increased by
30–40%, while its half-life showed a tremendous increase from 2 h to 25 days at ambient conditions
in comparison to free HRP [90]. A greater improvement in enzymatic activity (80%) was observed
in glucose oxidase (GOx) when loaded on SF films [91]. Moreover, SF-loaded GOx demonstrated
enhanced thermal and pH stability [92]. Topical application of SF lyogels (gel system in which the pores
are filled with both organic and non-organic solvents) containing hydrocortisone in a mouse model of
atopic eczema resulted in decreased expression of IgE and enhanced the efficacy of hydrocortisone
compared to the commercially available hydrocortisone cream [93]. Moreover, SF lyogels have also
been used for stabilising monoclonal antibodies. The lyogels achieved sustained release of IgG1 over
160 days and the release rate was found to be inversely proportional to the SF concentration [19].
In addition to drug stabilisation, SF has also been investigated for DNA preservation in order to protect
the DNA from the potential destabilising conditions such as temperature and UV radiation. In a recent
study porous cellulose paper was coated with SF and used to preserve the DNA extracted from human
dermal fibroblast cells [23]. The results showed that the DNA integrity was maintained for 40 days
following 10 h of UV radiation at relatively high temperature (37–40 ◦C) [23].
4.2. Controlled Drug Release
Controlled release drug delivery systems are aimed at releasing the encapsulated API in specified
amounts over a specified period of time. One application of such systems is sustained drug release
to maintain the therapeutic concentrations of the drug in the blood or site of action for a longer
duration which is of great importance for the treatment of chronic diseases. Moreover, sustained
drug release reduces the administration frequency and the adverse drug reactions which results in
increased patient compliance [22]. Most of the currently available controlled release formulations in
the market are composed of synthetic polymers such as PEG and PLGA because they provide desirable
pharmacokinetic and pharmacodynamic properties [94]. Although PLGA is approved by FDA as a safe
Pharmaceutics 2019, 11, 494 10 of 22
ingredient in pharmaceutical products, the processing requirements might restrict its utilisation in
certain controlled release formulations. Therefore, more recently, natural polymers such as SF which
offer tunable sustained release kinetics and stabilization of the loaded APIs have gained more attention
for use in controlled drug release systems.
One of the unique properties of SF is its ability to undergo diverse structural transformations
at the molecular level. The most investigated structural transformation in SF is the change in the
ratio of α-helix to β-sheet content. For example, the permeability and release kinetics of the SF films
are affected by the percentage of β-sheet structure [7]. The mechanism of controlled release from SF
films was studied previously by Hines and Kaplan using different models [95]. The release kinetics of
FITC-dextran from methanol-treated and untreated SF films was evaluated as a function of molecular
weight of FITC-dextran. The methanol-treated films maintained higher percentage of the loaded
FITC-dextran compared to the untreated films which was directly proportional to the molecular weight
of FITC-Dextran [95]. In a more recent study, the release profile of the anticancer drug epirubicin
from five Heparin-SF films (HEP-SF) treated with methanol (MeOH) or glycerol was investigated and
it was found that using different ratios of glycerol in the HEP-SF nanofilm formulation affects the
β-sheet content of the nanofilm leading to a modification in the release profile of epirubicin from the
nanofilm (Figure 4). This mechanism-causal relationship between SF conformation and release profile
also influenced the degree of degradation [7].
Figure 4. Total epirubicin (EPI) release profile from SF nanofilm depending on the ratio of the added
glycerol and the solvent treatment. Reprinted from Reference [7] with permission from the American
Chemical Society.
In a novel study conducted by Yavuz et al. [27] SF was formulated into insertable discs that can
encapsulate either IgG antibody or human immunodeficiency virus (HIV) inhibitor 5P12-RANTES.
Three different formulations were prepared by SF layering, water vapor annealing, and methanol
treatment. These formulations managed to stabilize the protein cargo and to modify its release profile.
High concentrations of IgG were released in a relatively short time from the formulation treated
with methanol due to the highly porous structure in comparison to the other two formulations that
demonstrated a slower and more controlled release. In the case of 5P12-RANTES, the water vapor
annealing showed a sustained release for 31 days and this released protein could inhibit HIV infection
in both blood and human colorectal tissue [27].
Controlled release from SF nanoparticles and microspheres has been studied extensively in the
past decade. In an attempt to control SF particle features, a recent study conducted by Song et al. [43]
demonstrated pH-controlled release of curcumin from SF nanoparticles for up to 20 days with lower
pH promoting the release. Moreover, the SF nanoparticles had higher cellular uptake and induced
significantly higher growth inhibitory effect in MDA-MB-231 cells compared to curcumin solution
(Figure 5).
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Figure 5. Representative microscopic images of MDA-MB-231 cells incubated with free curcumin ((a)
and (b), curcumin amount (10 µg/mL), equivalent to the curcumin amount in CMSPs (curcumin loaded
magnetic SF core−shell nanoparticles) and CMSPs ((c) and (d), 30 µg/mL) for 4 h. The cell nucleus
and cytoskeleton were stained with DAPI (blue) and Texas red (red); all images were taken with an
AF6000 microscope (Leica). Comparing the images in (a) and (b) to (c) and (d), it can be seen that
CMSPs significantly improve the cellular uptake of the curcumin. Reprinted from Reference [43] with
permission from the American Chemical Society [2017].
Another study developed SF microspheres (2 µm) using DOPC
(1,2-dioleoyl-sn-glycero-3-phosphocholine) lipid vesicles as a templates [96]. The physically
cross-linked β-sheet structure of SF and the residual DOPC in the microspheres played key roles in
controlling the release of loaded enzyme (HRP) [96].
In addition to the controlled release systems composed of SF as their main component, SF has also
been used as coating to modify the release kinetics of drug delivery systems made of other polymers.
SF, as a biopolymer, can be processed in aqueous conditions and crosslinked by different methods.
Therefore, SF solution has been utilised for single or multilayer coating of different pharmaceutical
preparations. In a study conducted by Pritchard et al. [97], the adenosine release from SF encapsulated
powder reservoirs was evaluated as a function of reservoir coating thickness. The coating thickness
was varied by changing the concentration of the silk coating solution and the number of coating
layers applied. Increasing the coating thickness or the crystallinity of the SF delayed adenosine burst,
decreased average release rate, and increased the duration of release [97]. Eliminating infections by
releasing antibiotics such as vancomycin from biodegradable microspheres is a very effective strategy.
However, maintaining the antibiotic concentration within the therapeutic window over the required
treatment time remains a challenge [98]. A recent study has addressed this challenge by coating
vancomycin-loaded poly(ε-caprolactone) (PCL) microspheres with SF to reduce the burst release
of vancomycin [98]. The PCL microspheres were prepared by double emulsion (W1/O/W2) solvent
evaporation/extraction process and the coating was performed by suspending the microspheres in
the SF coating solutions (0.1%, 0.5% or 1%). Methanol was used to induce SF transformation from
α-helix to β-sheet [98]. The microspheres coated with 0.1% SF showed smooth surface and presented
a better release profile. By increasing the SF concentration, more cracks and defects were detected
(Figure 6) [98].
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Figure 6. Scanning electron microscope (SEM)images of microspheres coated with 0.1% SF (A), 0.5% SF
(B) and 1% SF (C). Microsphere coated with 0.1% SF showed a smooth surface without defects or cracks.
Microspheres coated with 0.5% and 1% SF showed poor coating comprised of numerous surface defects
and cracks in the film structure (bar size 50 mm). In vitro release of vancomycin from microspheres
coated with different concentration of SF (D). Reprinted from [98] with permission from Taylor &
Francis Online [2011].
Many studies have focused on improving the efficiency of the current nanoformulations and
increasing the bioavailability of the loaded drugs by using adhesive excipients. For example, ocular
drug delivery is a very challenging task and requires highly optimized formulations due to the unique
environment in the eye. Because of the low ocular bioavailability, the frequency of applying the
eye drops is usually high which can cause cellular damage at the ocular surface [99]. Increasing the
residence time of drug on the eye surface will not only improve the efficiency of the therapy but also
reduce the frequency of administration. A study presented by Dong et al. [16] prepared SF-coated
liposomes loaded with ibuprofen for ocular delivery. The SF-coated liposomes exhibited better cell
adhesion in human corneal epithelial cells (HCEC) compared to the conventional liposomes. Moreover,
the drug release and permeation rates could be tuned by adjusting the concentration of the SF [16].
Another study also used SF coating on emodin-loaded liposomes (SF-ELP) to enhance keloids cell
adhesion [100]. This study showed a selective targeting of keloids cells in comparison to normal cells
which was achieved through interaction between SF and the cell in contrast to ligand targeting which is
achieved by binding to specific receptors on the cell surface. SF-coating also limited Brownian motion
and increased the probability of the nanoparticles attaching to the cell surface [100].
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Table 2. SF-based drug delivery systems.
Type of Drug
Delivery System
Associated API Results References
SF sponges Erythromycin
Sustained drug release and prolonged
antimicrobial activity against
Staphilococcus Aureus
[3]
SF films
Horseradish peroxidase (HRP) Enhanced stability [36]
Glucose oxidase (GOx) Increased enzymatic activity [91]
FITC-dextran Controlled drug release [95]
Epirubicin Controlled drug release [7]
SF lyogels
Hydrocortisone
IgG
Enhanced efficacy
Enhanced stability and sustained
release
[84]
Insertable SF discs
IgG and HIV inhibitor
5P12-RANTES
Enhanced stability and modified
release profile
[27]
SF nanoparticles Curcumin
Modified release profile and enhanced
cellular uptake
[43]
SF microspheres Horseradish peroxidase (HRP) Modified the release profile [96]
SF-coated PCL
microspheres
Vancomycin Modified the release profile [98]
SF-coated liposomes
Ibuprofen
Enhanced adhesion to human corneal
epithelial cells, tunable drug release
[16]
Emodin Selective targeting of keloid cells [100]
4.3. Gene Delivery
Gene delivery is defined as the introduction of genetic material including DNA and RNA into
the targeted cells to regulate the expression of particular genes or direct the synthesis of specific
proteins in order to treat disorders caused by dysregulation or malfunction of those proteins [101].
Using plasmid DNA (pDNA) is more common than RNA in gene delivery, especially to cancer
cells [38,101]. Despite that more than 2600 clinical trials on gene therapy have been carried out in
38 countries since the early 1990s, none of these therapies have been granted FDA approval [102].
One of the main reasons why the gene-based formulations have failed to find their way to the
market is that the majority of these formulations use viruses as gene vectors. Viral vectors
usually give rise to concerns regarding systemic toxicity and immune response [38]. Therefore,
the recent studies have shifted their focus toward non-viral vectors using biocompatible polymeric
formulations. Non-viral gene delivery systems are typically designed using cationic lipids such as
DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) or positively charged synthetic polymers
such as polyethyleneimine to provide a safer alternative to viral vectors [103]. However, transfection
efficiency, target specificity and cytotoxicity of the common non-viral vectors remain obstacles to
overcome. In addition to biocompatibility, SF has demonstrated DNase resistance and high transfection
efficiency. These propertiesmake SF a preferable polymeric vector for gene delivery [104]. Using genetic
engineering, SF can be modified to gain more functions that suit the desired application. For example,
modifying silk by adding PLL (poly(L-lysine)) sequences resulted in higher transfection efficiency
of pDNA in human embryonic kidney (HEK) cells [105]. A later study has used SF bioengineered
with PLL domains to interact with both pDNA and tumor-homing peptide (THP) for targeted pDNA
delivery [85]. Even though silk based gene delivery vectors have shown high transfection efficiency
and an acceptable degree of specificity [85], higher specificity is required for more effective targeted
cancer therapy. An improved silk-based gene delivery system has been developed by adding F3 and
Lyp1 peptides to recombinant silk proteins with a relatively high content of THP (25 mol%, 3.4 kDa/13.6
kDa) [103]. F3 peptide is capable of specifically binding to MDA-MB-435 cancer cells while Lyp1
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binds specifically to tumor lymphatics and can also induce cell death in MDA-MB-435 cells [106–109].
The designed system achieved specific delivery of pDNA to the tumorigenic cells [103].
Another approach to capture DNA is using cationic polymers such as polyethyleneimine (PEI)
within the silk formulation [9]. Luo et al. [4] developed cationic SF scaffolds by coating PEI on SF
scaffold for delivery of vascular endothelial growth factor 165/angiopoietin-1 coexpression plasmid
DNA (pDNA & VEGF165–Ang-1). PEI coating converted the surface charge from negative to positive
through amidation reaction between the spermine and the carboxyl groups in the side chains of SF.
The positive surface charge allowed the SF scaffold to form complexes with pDNAwhich demonstrated
higher transfection efficiency and lower cytotoxicity than PEI/DNA complexes [4]. SF coated PEI/DNA
complexes were also used to transfect HEK 293 and human colorectal carcinoma HCT 116 cells, and the
system exhibited higher selectivity for HCT 116 compared to HEK 293 [110].
Recently, Song et al. [9] investigated the delivery of oligodeoxynucleotides (ODNs) toMDA-MB-231
breast cancer cells. The addition of SF to the nanoparticle formulation not only increased the cellular
uptake of ODN (70%) but also significantly reduced its cytotoxicity (Table 3) [9]. Cell-penetrating
peptides (CCPs) have also been used in SF-based gene delivery systems due to their ability to
penetrate or destabilize cellular membranes. When designing a non-viral carrier for gene delivery,
CCPs are considered among the preferred components to facilitate clathrin-dependent endocytosis
of the particles [111,112]. Functionalization of silk protein with ppTG1 which is a CPP increased its
transfection efficiency for pDNA in HEK 293 cells compared to unmodified silk (Table 3) [113].
Table 3. SF -based formulations for gene delivery.
Formulation Gene Cell line Reference
Recombinant silk–elastin-like polymer
hydrogels (SELPs)
Adenovirus
Ad1–CMV2–LacZ3
Head and neck
cancer in mice
[114]
pDNA4
(pRL5-CMV-luc6)
NA [115]
Ad–Luc–HSVtk7
Head and neck
cancer in mice
[116]
3D porous scaffold Adenovirus Ad-BMP78 Human BMSCs [117]
Bioengineered silk films pDNA (GFP9) Human HEK cells [105]
Spermine modified SF
pDNA and
VEGF165–Ang-110
In vivo-rat [4]
SF-Coated PEI/DNA Complexes pDNA (GFP)
HEK 293 and HCT
116 cells
[110]
SF layer-by-layer assembled
microcapsules
pDNA-Cy511 NIH/3T3 fibroblasts [118]
Bioengineered silk–polylysine–ppTG1
nanoparticles
pDNA
Human HEK and
MDA-MB-435 cells
[113]
Magnetic-SF/polyethyleneimine
core-shell nanoparticles
c-Myc12 antisense
ODNs13
MDA-MB-231 cells [9]
1 Adenovirus; 2 cytomegalovirus promoter gene; 3 beta galactosidase reporter gene; 4 plasmid DNA; 5 renilla
luciferase; 6 luciferase reporter gene; 7 herpes simplex virus thymidine kinase gene; 8 bone morphogenic protein;
9 green fluorescent protein; 10 vascular endothelial growth factor and angiopoietin-1; 11 fluorescent probe; 12 MYC
Proto-Oncogene; 13 oligodeoxynucleotides.
5. Modification of SF for Enhanced Delivery
5.1. SF Bioconjugates
There are many protein-based drugs that have shown a very short half-life in the body. In order to
enhance their in vivo stability, an approach has been designed to utilize SF by forming bioconjugates.
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A covalent bond between the protein or enzyme and SF can be formed by the cross-linking reagents [5].
SF consists of 18 different amino acids among which 10% are polar amino acids such as serine and
lysine with hydroxyl and amino groups in their side chains. These functional groups in SF can be
covalently conjugated to polar groups in other proteins such as insulin using bifunctional reagent
glutaraldehyde [119]. SF-insulin (SF-Ins) bioconjugate not only demonstrated higher in vitro stability
than bovine serum albumin-insulin (BSA-Ins) conjugate, but also prolonged the pharmacological
activity 3.5 times in comparison to native insulin [119]. Covalent conjugation of growth factor BMP-2 to
SF using carbodiimide chemistry preserved BMP-2 activity and also reduced its degradation rate due to
reduction in its unfolding rate as well as protecting it from proteases [120]. Immobilization of enzymes
on silk particles has also been studied recently to enhance the catalytic efficiency of enzymes by
improving enzymatic stability. SF has several active amino groups that have the potential for covalent
binding to several enzymes to immobilize them (Figure 7) such as catalase immobilization on SF
particles via tyrosinase crosslinking [121]. SF films have been also used to immobilize antibodies such
as mouse IgG simply through the conformational transition to fabricate biocompatible biosensors [122].
The immobilizationwas achieved by slowly drying concentrated SF solution to reach the semisolid state
and then blending it with antibody solution before complete drying. It was found that more antibody
was immobilized on the surface of SF film by controlling the conformational changes during the drying
process in comparison to covalent methods [122]. These results indicate that SF can be functionalized
with antibodies with or without crosslinking agents, offering a wide range of biomedical applications.
Figure 7. (A) Possible routes toward chemical modification of amino acids of silk proteins. Reprinted
from [50] with permission from Elsevier. [2014].(B) The new properties obtained by SF when
functionalised or modified in different positions.
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5.2. Functionalization of SF with Ligands
One of the fundamental advantages of nanoparticles is the greater surface area to the volume ratio
compared to larger particles. This property is essential for encapsulating the APIs such as anticancer
agents and delivering them to the site of action. Moreover, the loaded APIs must be delivered at
a proper concentration to cause the required effect on the target cells and minimise the damage to
other cells [123]. However, recent studies have found that engineered particles with the optimum
size and shape are limited to less than 1% tumor tissue accumulation [124]. Therefore, decorating
polymeric nanocarriers with a targeting molecule has emerged as an effective approach to increase
the specificity of the nanoparticles for the targeted cell lines [125]. As mentioned earlier SF has
several active amino groups (Figure 7) which can be used for binding to other macromolecules [126].
For example, Arg-Gly-Asp (RGD) sequence that acts as a ligand for cell surface integrin receptors
can be linked to SF particles to enhance their attachment to the certain cancer cells that overexpress
integrins [127]. In a similar fashion, due to the overexpression of folate receptors (FR) in a wide
range of tumor cells, modifying the surface of the silk nanoparticles with folate could be used as
a tumor-targeting strategy [128]. Folate-conjugated SF particles (SF-FA) were used to enhance targeted
delivery of doxorubicin (DOX) to human breast adenocarcinoma cell line (MDA-MB-231) [127]. Folate
decoration on silk particle not only increased the retention of the nanoparticles at the tumor site but also
promoted cellular uptake of the particles [129]. DOX incorporated in SF-FA nanoparticles demonstrated
3-folds higher cytotoxic activity in comparison to free DOX in vitro. Moreover, conjugation of folate
to SF nanoparticles changed their cellular uptake mechanism from passive diffusion (free DOX) to
endocytosis [126]. Another example of specific targeting using functionalized SF is modification of
SF with human epidermal growth factor receptor 2 (Her2) which is overexpressed in 30% of breast
carcinomas for targeted drug delivery to breast cancer cells [130]. An alternative functionalization
approach involves using tumor-specific ligands such as nucleic acid sequences like CpG-siRNA [131].
6. Conclusions
Silk is a versatile biomaterial with great potential for drug and gene delivery applications. SF
has been used as a naturally derived biopolymer for development of various types of drug delivery
systems including hydrogels, SF films, microparticles and nanoparticles using a variety of fabrication
methods. Each of these SF-based systems have shown promising features for different biomedical
applications. SF micro- and nanoparticles have been used for delivery of different types of drugs such
as curcumin, doxorubicin and ibuprofen as well as pDNA to various types of cells in a time-specific or
site-specific manner. SF films have been used for controlled release of drugs such as dextran, epirubicin,
and biological agents such as IgG and HIV inhibitor 5P12-RANTES. In addition, they have been used
to stabilise biological agents such as horse radish peroxidase (HRP), glucose oxidase, vaccines and
monoclonal antibodies in order to enhance their shelf life. Moreover, conjugation of SF to biomolecules
such as insulin and BMP-2 has been employed as a strategy to sustain their release and prolong
their biological activity. Functionalisation of SF with biological recognition elements such as RGD
sequence, folate and Her2 has been used for tissue-specific drug delivery. In addition to the SF-based
drug delivery systems, SF has also been used for coating the surface of polymeric microparticles and
liposomes in order to modify their release kinetics or enhance their cell adhesion. However, despite
all the advances made in the fabrication of SF-based constructs for biomedical and pharmaceutical
applications, there is still lack of sufficient studies on the applications of bioengineered or structurally
modified silk for tissue-specific targeted drug and gene delivery. Also, modifying the physichochemical
and mechanical properties of the SF through miximng it with other natural or synthetic polymers in
order to develop tailored SF-based biomaterials is another area to be further explored.
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